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ABSTRACT: Biopharmaceuticals such as protein and peptide-based drugs are often
produced by fermentation processes where it is necessary to monitor the amount and
quality of the product expressed during fermentation and for release testing of the final drug
product. Standard procedures involve surface-based ligand binding technologies such as
enzyme-linked immunosorbent assay and biolayer interferometry, or extensive purification
using, e.g., preparative chromatography followed by spectrophotometric protein
quantification. The multistep nature of these methodologies leads to lengthy protocols
and renders real-time process control impractical. Recently, flow-induced dispersion
analysis (FIDA) was introduced as a novel in-solution ligand binding technology, requiring only nano/microliter sample volumes.
FIDA is based on Taylor dispersion analysis in narrow fused silica capillaries and provides the hydrodynamic radius of the binding
ligand and complex in addition to the detailed binding characterization. Here, we demonstrate the use of FIDA for quantification of
monoclonal IgG antibodies (rituximab) directly in mammalian cell fermentation broth with only 4 min of analysis time. The FIDA
assay utilizes a small anti-IgG affibody, conjugated to a fluorophore, as a selective rituximab binder. The apparent change in the
hydrodynamic radius of the affibody, as it interacts with known concentrations of rituximab, is used for generating a binding curve in
a blank fermentation medium, and hence determining the dissociation constant and complex size. Finally, the binding curve is
utilized for quantifying the rituximab titer concentration in clarified fermentation broth samples.
■ INTRODUCTION
The vast majority of biopharmaceuticals are produced by
fermentation processes via genetically modified cell lines based,
primarily, on mammalian, bacterial, or yeast cells.1−3 These
cells are exploited for their inherent protein synthesis
apparatus, which is harnessed for assembling, folding, and
expressing protein-based drugs. The cells require complex
media for sustainable growth and satisfactory protein
expression. Furthermore, the cells express host cell proteins
(HCPs), as part of their metabolism, and may release cellular
debris components (DNA, cell wall, and HCPs) into the
growth medium upon apoptosis. Consequently, the growth
medium, i.e., fermentation broth, is, at the end of a
fermentation process, a complex solution. This presents a
substantial challenge to most analytical assays; thus,
purification steps are typically implemented prior to anal-
ysis,4−7 which impede fast and inexpensive selection of clones
and further cell line optimization. Currently, surface-based
methodologies such as biolayer interferometry (BLI) and
enzyme-linked immunosorbent assay (ELISA) are the
preferred methods for assessing IgG titers via immobilization
of selective ligands (e.g., protein A).8,9 However, these
methods rely on surface-based interactions and thus may not
report the actual in-solution titer due to nonspecific surface
adsorption.
Flow-induced dispersion analysis (FIDA) has emerged as a
new immobilization-free ligand binding technology with
abilities for in-solution characterization of protein size,
stability, and binding affinity.10−14 Briefly, FIDA utilizes Taylor
dispersion analysis (TDA) in narrow capillaries under a
laminar flow for measuring the change in the apparent
hydrodynamic radius of a selective ligand (termed the
indicator) as it interacts with the analyte of interest. The
apparent hydrodynamic radius (i.e., size) of the indicator is
measured at different analyte concentrations and thereby forms
the basis for generation of a binding curve and determination
of the dissociation constant (Kd) and complex size.
Furthermore, the binding curve serves as a standard curve
for selectively quantifying analyte concentrations in unknown
samples based on the apparent indicator size measured.
Here, we present a FIDA-based approach for quantifying the
rituximab titer directly in clarified Chinese hamster ovary
(CHO) cell fermentation broth using an anti-IgG affibody as
the indicator. The FIDA assay was developed in an
uninoculated fermentation medium using known quantities
of rituximab and subsequently utilized for quantifying the
rituximab titer in CHO cell fermentation broth samples. The
titers measured by the FIDA assay are in good agreement with
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traditional measurements performed using UV−vis absorption
spectroscopy, following a protein A-based purification
procedure.
■ EXPERIMENTAL SECTION
Equipment. The FIDA experiments were conducted on a
FIDA 1 instrument employing light-emitting diode (LED)-
induced fluorescence detection (FIDA Biosystems ApS,
Copenhagen, Denmark) with an excitation wavelength of
480 nm and a high-pass emission filter (515 nm cutoff).
TDA experiments were performed on a PrinCE NEXT 870
instrument (PrinCE Technologies, Emmen, The Netherlands)
employing an ActiPix D100 UV imaging system (Paraytec Ltd.,
York, United Kingdom) for detection at 214 nm.
PEG-coated fused silica capillaries (inner diameter: 75 μm,
outer diameter: 375 μm, length total: 100 cm, length to
detection window: 84 cm) from FIDA Biosystems were used.
Materials and Chemicals. Rituximab (lot H0156B04,
144,544 kDa) from Roche (MabThera, Basel, Switzerland),
clarified (without cells) CHEF1 CHO cell fermentation broths
from two parallel runs (TF262, PM01, and PM02
respectively), and uninoculated fermentation media were
obtained from AGC Biologics (Soeborg, Denmark). The
anti-IgG affibody (cat. no. ab31900) was purchased from
Abcam (Cambridge, UK). Alexa Fluor 488 C5-maleimide was
purchased from Thermo Fisher (Waltham, Massachusetts,
USA). Dithiothreitol (DTT) and glycine were purchased from
Sigma Aldrich (St Louis, Missouri, USA). Sodium dihydrogen
phosphate monohydrate and disodium hydrogen phosphate
dodecahydrate were purchased from Merck (Darmstadt,
Germany). Dimethyl sulfoxide (DMSO) was obtained from
EMP Biotech (Berlin, Germany). Tris ultrapure was obtained
from ICN Biomedical (Aurora, Ohio, USA). Ultrapure water
(18.2 MΩ-cm at 25 °C) was tapped from a water purification
system (SG Ultraclear, SG Water, Barsbüttel, Germany).
Assay Buffer. A 67 mM phosphate buffer, pH 7.4, was
prepared with ultrapure water, filtered through a Q-max 0.45
μm nylon syringe filter (Frisenette, Knebel, Denmark), and
used as the assay buffer.
Fluorophore Labelling of the Anti-IgG Affibody. The
anti-IgG affibody (200 μg at 1 mg/mL) was reduced in 0.02 M
DTT for 2 h at room temperature. Subsequently, the DTT was
removed by buffer exchange into the assay buffer utilizing a
pre-equilibrated PD SpinTrap G-25 column (GE Healthcare,
Marlborough, Massachusetts, USA). Alexa Fluor 488 C5-
maleimide was dissolved in DMSO to a stock concentration of
10 mM and then added to the affibody solution with a molar
ratio of 19:1 (Alexa Fluor/affibody) immediately after the
buffer exchange. The labelling reaction was incubated for 2 h at
room temperature and subsequently purified in the assay buffer
utilizing a pre-equilibrated SpinTrap G-25 column.
The concentration of the affibody−alexa488 conjugate was
determined using a microvolume spectrophotometer (Nano-
Drop 2000C, Thermo Fisher Scientific, Wilmington, Delaware,
USA), using the molar absorption coefficient of alexa488 (ε =
72,000 cm−1 M−1) at 493 nm15 since the anti-IgG affibody
does not contain any tyrosine or tryptophan residues.
Protein A Purification Buffers. The equilibration and
binding buffers were a 20 mM phosphate buffer, pH 7.0; the
elution buffer was 0.1 M glycine−HCl, pH 2.7; and the
neutralizing buffer was 1 M Tris−HCl, pH 9.0. All buffers were
prepared with ultrapure water.
FIDA and TDA Procedures. The PEG-coated capillary
was flushed and equilibrated prior to sample analysis with the
67 mM phosphate buffer, pH 7.4, at 1500 mbar for 5 min. The
analyte sample was injected at 1500 mbar for 45 s followed by
injection of the indicator sample at 50 mbar for 10 s (39 nL,
corresponding to 1% of the capillary volume). Subsequently,
the injected indicator sample was mobilized toward the LED
detector with the analyte sample at 400 mbar for 240 s. The
capillary, samples, and buffer vials were kept in a temperature-
controlled environment at 25 °C inside the instrument. All
samples were analyzed in triplicate.
Development of the FIDA Assay. The hydrodynamic
radius of the unconjugated anti-IgG affibody was measured
using TDA at a concentration of 1 mg/mL in a neat phosphate
buffer.
Subsequently, the indicator, anti-IgG affibody−alexa488, was
diluted to a fixed indicator concentration of 20 nM in varying
concentrations (0−10% v/v) of CHO cell fermentation broth
(TF262, PM02). The fermentation broth was diluted with the
assay buffer. All samples were preincubated for >10 min to
attain equilibrium prior to the FIDA measurements.
Standard Curves for Rituximab Quantification in the
Fermentation Broth. Standard curves were established in 0.3
and 5.0% v/v uninoculated fermentation media. The indicator,
anti-IgG affibody−alexa488, was added to provide a fixed
indicator concentration of 20 nM in the medium with varying
and known concentrations of rituximab (0−2000 nM). All
samples were preincubated for >10 min to attain equilibrium
prior to the FIDA measurements.
Determination of the Rituximab Titer by FIDA.
Quantification of rituximab in two parallel CHO cell
fermentation broths (TF262 PM01 and TF262 PM02) was
performed for three different concentrations of fermentation
broth (0.05, 0.075, and 0.10% v/v). The indicator, anti-IgG
affibody−alexa488, was added to provide a fixed indicator
concentration of 20 nM, and an uninoculated fermentation
medium was added to reach a final medium concentration of
5% v/v (i.e., 4.95, 4.925, and 4.90% v/v, respectively). All
samples were preincubated for >10 min to attain equilibrium
prior to the FIDA measurements.
Determination of the Rituximab Titer by Protein A
Purification and UV Spectrophotometry. The rituximab
content was also determined using disposable protein A HP
SpinTrap columns from GE Healthcare, following the supplier
instructions (#28-9031-32). Three parallel purification runs
were performed for each of the two fermentations (i.e., TF262
PM01 and TF262 PM02), and every column was loaded with
300 μL of fermentation broth. After purification, the
concentration of rituximab was determined utilizing a micro-
volume spectrophotometer (NanoDrop 2000C) and the
extinction coefficient of rituximab (ε = 1.7 cm−1 (mg/
mL)−1) at 280 nm.16
Data Analysis. The Taylorgrams were processed using the
FIDA software, version 1.03 (FIDA Biosystems ApS,
Copenhagen, Denmark), for calculating the apparent hydro-
dynamic radius of the indicator (anti-IgG affibody−alexa-488)
at each analyte concentration. The Taylorgram fraction setting
was consistently fixed to 75% for all data points, and minor
fluctuations in sample viscosity were corrected according to a
reference measurement of the indicator in a neat phosphate
buffer, as previously described.10
Typically, the following binding isotherm is used for FIDA
assays, assuming an indicator concentration below the
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where CI and CA are the formal concentrations of the indicator
and analyte, respectively. The details of the excess indicator
binding isotherm are described in the Supporting Information.
■ RESULTS AND DISCUSSION
Development of the FIDA Assay. Protein quantification
using FIDA is based on an indicator molecule (anti-IgG
affibody) interacting selectively with the analyte protein
(rituximab, IgG) in the sample matrix. An apparent change
in the indicator size due to the interaction with the analyte
present is used for the quantification. An anti-IgG affibody was
selected as the indicator due to an expected selectivity towards
the Fc region of rituximab and, hence, not interacting with
other components of the sample matrix. The affibody was
fluorescently labelled at the dedicated C-terminal cysteine for
single-point modification,17 ensuring selective and high
sensitivity measurements in the complex samples. Further-
more, the affibody was considered a promising indicator due to
the small size (7 kDa) relative to rituximab (145 kDa), thus
potentially providing high sensitivity and a wide dynamic
range. Other anti-IgG specific ligands, e.g., protein A (similar
specificity as the affibody used in the present work), protein G,
aptamers, or nanobodies,18 might be suitable for FIDA-based
rituximab quantification as well. The specificity of the methods
is directly linked to the specificity of the interaction between
the affibody and the constant region of the antibody. As the
affibody recognizes the constant region of the antibody, the
same methodology is applicable to the detection of any human
IgG antibody.
The hydrodynamic radii of the unconjugated dimeric
affibody (14 kDa) and monomeric affibody−alexa488
conjugate (7 kDa) were determined in a neat phosphate
buffer by TDA and FIDA to 3.27 ± 0.05 and 2.24 ± 0.10 nm,
respectively. These values were slightly higher than expected
for globular proteins,19 thereby suggesting a relatively loose
conformation.
Subsequently, a feasibility study was performed to assess
whether the anti-IgG affibody could be measured directly in a
clarified fermentation broth containing rituximab (TF262
PM02). The apparent hydrodynamic radius of the anti-IgG
affibody was measured in increasing fermentation broth
concentrations using FIDA (Figure 1). The apparent hydro-
dynamic radius of the anti-IgG affibody was found to increase
from 2.2 to a plateau at ∼8 nm (Figure 1), thereby indicating
affibody binding to rituximab.
It was attempted to fit the data in Figure 1 to the binding
isotherm assuming a 1:1 binding stoichiometry (eq 1).
However, the binding curve appeared steeper than anticipated,
which could point to the affibody concentration being higher
than the Kd at low rituximab concentrations. Therefore, the
data was also fitted to an excess indicator binding isotherm (eq
2), resulting in a significantly better fit (Figure 1, orange line).
This was further investigated by a second set of experiments in
which the affibody concentration was reduced from 20 to 5
nM. Here, a shift in the binding isotherm was observed (Figure
S1 in the Supporting Information), indicating that the affibody
was indeed in excess at low rituximab concentrations. This
scenario has previously been described theoretically for FIDA
experiments.13
The Taylorgram overlay at the 0 and 10% v/v fermentation
broth in Figure 1 (insert, corrected for viscosity-related
differences20) revealed a noteworthy change in the peak area,
thereby indicating adsorption of the indicator (i.e., affibody) to
labware surfaces (e.g., vials and capillary) at low fermentation
broth concentrations. Here, the fermentation broth was simply
added to prevent indicator (and potentially rituximab)
adsorption to the labware surfaces. Taylorgrams of indicator
peak areas depicted as a function of fermentation broth
concentration (Figure S2) showed increased peak areas and
minimized adsorption at broth concentrations above 0.05% v/
v. This initial set of experiments demonstrated that the FIDA
assay was capable of characterizing interactions directly in a
Figure 1. Apparent hydrodynamic radius of the 20 nM anti-IgG
affibody−alexa488 as a function of fermentation broth concentration
(PM02 (containing rituximab), 0−10% v/v) determined by FIDA at
25 °C (black open circles, n = 3, error bars represent standard
deviation). The dotted black line and solid orange line represents
fitting to 1:1 (R2 = 0.980) and excess indicator (R2 = 0.990) binding
isotherms, respectively. (Insert) visual comparison of viscosity-
corrected Taylorgrams at 0 and 10% v/v fermentation broth (solid
and dashed line, respectively).
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clarified fermentation broth. We did not observe any
nonspecific binding to matrix components.
Standard Curves for Rituximab in Fermentation
Media. Rituximab standard curves (0−2000 nM) were
established in 0.3 and 5% v/v uninoculated (i.e., blank)
fermentation media in order to define optimal conditions for
quantification. The apparent hydrodynamic radius of the anti-
IgG affibody increased with an increasing rituximab concen-
tration, as expected (Figure 2), and a plateau was reached
around 8 nm (Figure 2), indicating full binding, in line with
the initial experiments (Figure 1).
As expected from the assay development experiment (Figure
1), the excess indicator isotherm (eq 2) was most suitable for
the binding curves (Figure 2). This was further verified by the
binding parameters summarized in Table 1. Here, the R2-values
for the excess ligand binding isotherm were superior to the 1:1
in terms of describing the data. The affinity was notably high,
and using the 1:1 binding model (eq 1), the apparent
dissociation constants (Kd) were in the low nM range,
indicating that the indicator concentration is not lower than
the Kd. While eq 1 provides an apparent Kd for the interaction,
it would, however, require lower indicator concentrations to
quantify the true Kd using this model. In this case, it is
therefore more accurate to apply the excess indicator model
(eq 2). For quantification, the binding curve is used as a
standard curve linking the apparent size to antibody
concentration. When the limit of quantification (LOQ) is
defined as 10 times the relative standard deviation of the blank
sample, an LOQ of 0.9 nM or 135 ng/mL is determined, which
is about two orders of magnitude lower than HPLC
procedures.21 In the FIDA methodology, there is a direct
link between the apparent size, fraction unbound, and
ultimately concentration. There is no requirement for linearity
for connecting the apparent size, fraction bound, and
concentration.
The standard curves in 0.3 and 5% fermentation media were
highly similar (Figure 2). However, it was decided to perform
the rituximab quantification in the 5% v/v fermentation
medium since this concentration was superior in terms of
eliminating nonspecific surface adsorption (Figure S2). The
standard curve covers rituximab quantification in the 5% v/v
fermentation medium, thus the samples (PM01 and PM02)
Figure 2. Apparent hydrodynamic radius of the 20 nM anti-IgG affibody−alexa488 as a function of rituximab concentration (0−2000 nM)
determined by FIDA at 25 °C. The black open diamonds and red open circles represent measurements in 0.3 and 5.0% v/v uninoculated
fermentation media, respectively (n = 3, error bars represent standard deviation). The solid black line and dotted red line represent fitting to (A)
1:1 and (B) excess indicator binding isotherms, respectively. Insert: visual comparison of viscosity-corrected Taylorgrams in a 5.0% v/v
uninoculated fermentation medium at 0 and 2000 nM rituximab (solid and dashed line, respectively).
Table 1. Fitted Binding Parameters (Standard Curves) in 0.3 and 5% Uninoculated Fermentation Medium, Representing Both
1:1 Binding Stoichiometry and Excess Indicator Models
medium concentration 0.3% v/v 5% v/v 0.3% v/v 5% v/v
binding isotherm model 1:1 (eq 1) 1:1 (eq 1) excess (eq 2) excess (eq 2)
indicator size (RI) (nm) 2.00 2.12 2.37 2.46
indicator-complex size (RIA) (nm) 8.22 8.23 7.84 8.03
dissociation constant, Kd (nM) 2.66 2.70 0.66 1.12
coefficient of determination (R2) 0.965 0.970 0.999 0.995
Table 2. Quantification of Rituximab in CHO Cell Fermentation Broth Samples TF262 PM01 and TF262 PM02a
TF262 PM01 TF262 PM02
fermentation broth concentration [% v/v] 0.05 0.075 0.10 0.05 0.075 0.10
rituximab concentration by FIDA [mg/mL] 1.34 ± 0.14 1.28 ± 0.07 1.38 ± 0.06 1.46 ± 0.02 1.34 ± 0.06 1.28 ± 0.04
rituximab concentration by UV spectrophotometry following protein A
purification
1.22 ± 0.08 1.41 ± 0.04
aThe rituximab concentration was found to be within the expected titer for a typical CHO cell fermentation process.1
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were diluted with the uninoculated fermentation medium in
order to be within the dynamic range of the binding curve
since the interaction was fully saturated at 5% broth as seen in
Figure 1. The excess indicator fitting model was chosen since it
fitted the data with the highest accuracy (Table 1).
Quantification of Rituximab in CHO Cell Fermenta-
tion Broth with the Anti-IgG Affibody Using FIDA. The
samples (PM01 and PM02) were diluted to fermentation
broth concentrations of 0.05, 0.075, and 0.10% v/v with a
blank fermentation medium and assay buffer to a final medium
concentration of 5% v/v. This approach was applied in order
to be within the dynamic range of the binding curve (Figure 2)
and eliminate nonspecific adsorption. The selected dilutions
were also chosen for verifying the concentration measurements
in the dynamic range of the standard curve. The apparent
hydrodynamic radius of the 20 nM anti-IgG affibody−alexa488
was measured in each dilution and related to an apparent
rituximab concentration using the standard curve (5% v/v,
Figure 2), which led to the results in Table 2 upon correction
for dilution.
Quantification of Rituximab in CHO Cell Fermenta-
tion Broth by Protein A Purification and UV Spec-
trophotometry. The content of rituximab in the fermenta-
tion broth samples (PM01 and PM02) was quantified using a
conventional method involving protein A-based solid phase
purification followed by quantification using UV absorbance at
280 nm.21,22 Although we employed spin columns (see the
Experimental Section), HPLC methodologies are also
applicable.21 Whereas an HPLC-based procedure often
requires sample preparation, a recent study reported a fast
(less than 5 min) HPLC-based procedure but with a detection
limit two orders of magnitude higher than the methodology
reported in the present work.21 The results are depicted in
Table 2. The rituximab titers determined by this approach are
in good agreement with the FIDA measurements. This
demonstrates that the developed FIDA method is compatible
with specific measurements in a clarified fermentation broth.
Furthermore, FIDA can measure selectively in a clarified
fermentation broth, thus eliminating any requirement for
purification prior to sample analysis, which, in combination
with a fully automated instrument, allows for a considerably
high throughput of samples with few procedural steps. The
simple FIDA methodology enables assessment of the in-
solution IgG titer in less than 4 min, thereby allowing nearly
real-time measurements of IgG titer during fermentation
processes.
■ CONCLUSIONS
The present work shows that FIDA is a viable technology for
direct (no sample pretreatment) quantification of the antibody
titer in a CHO cell fermentation broth (nanomolar sensitivity)
and for characterization of in-solution binding to monoclonal
antibodies. The developed FIDA assay utilized a selective anti-
IgG affibody as indicator and thereby accurately determining
the rituximab concentration without any preceding purification
process. This demonstrates that FIDA is characterized by being
highly tolerant to the sample matrix, hence, little or no sample
pretreatment is required. Furthermore, the developed method
characterized the affibody−rituximab interaction with regards
to determining the dissociation constant (Kd), complex size
(Rh), and binding stoichiometry.
This protocol may be extended to include a full functional
assessment of the antibody by assessment of specific target
binding. We thus envision that the FIDA methodology will
find applications in development and production of therapeutic
proteins.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsomega.0c00791.
Additional experimental details (PDF)
■ AUTHOR INFORMATION
Corresponding Author
Henrik Jensen − FIDA Biosystems ApS, 2100 Copenhagen,
Denmark; Department of Pharmacy, University of Copenhagen,
2100 Copenhagen, Denmark; orcid.org/0000-0001-6750-
2716; Email: Henrik.jensen@sund.ku.dk
Authors
Morten E. Pedersen − FIDA Biosystems ApS, 2100
Copenhagen, Denmark; Department of Pharmacy, University of
Copenhagen, 2100 Copenhagen, Denmark
Jesper Østergaard − Department of Pharmacy, University of
Copenhagen, 2100 Copenhagen, Denmark; orcid.org/0000-
0003-3448-4237
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsomega.0c00791
Author Contributions
All authors have given approval to the final version of the
manuscript.
Notes
The authors declare the following competing financial
interest(s): HJ, JO, and MEP have commercial interests in
FIDA Biosystems ApS. MEP and HJ are employees of FIDA
Biosystems ApS.
■ ACKNOWLEDGMENTS
AGC Biologics is acknowledged for providing samples and
reference materials. Financial support from the Innovation
Fund Denmark (grant no. 9065-00009B), the Market
Development Fund (grant no. 2016-10649), and Carlsberg
Foundation (grant no. 2013_01_0544) are gratefully acknowl-
edged.
■ REFERENCES
(1) Li, F.; Vijayasankaran, N.; Shen, A.; Kiss, R.; Amanullah, A. Cell
Culture Processes for Monoclonal Antibody Production. mAbs 2010,
2, 466−479.
(2) Kantardjieff, A.; Zhou, W. Mammalian Cell Cultures for
Biologics Manufacturing. Adv. Biochem. Eng./Biotechnol. 2014,
DOI: 10.1007/10_2013_255.
(3) dos Santos, N. V.; de Carvalho Santos-Ebinuma, V.; Pessoa
Junior, A.; Pereira, J. F. B. Liquid−Liquid Extraction of
Biopharmaceuticals from Fermented Broth: Trends and Future
Prospects. J. Chem. Technol. Biotechnol. 2018, 93, 1845−1863.
(4) Reusch, D.; Haberger, M.; Selman, M. H. J.; Bulau, P.; Deelder,
A. M.; Wuhrer, M.; Engler, N. High-Throughput Work Flow for IgG
Fc-Glycosylation Analysis of Biotechnological Samples. Anal. Biochem.
2013, 432, 82−89.
(5) Estes, S.; Melville, M. Mammalian Cell Line Developments in
Speed and Efficiency. In Mammalian Cell Cultures for Biologics
Manufacturing. Advances in biochemical engineering/biotechnology;
Springer, 2014; pp 11−33. DOI: 10.1007/10_2013_260.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00791
ACS Omega 2020, 5, 10519−10524
10523
(6) Dong, J.; Migliore, N.; Mehrman, S. J.; Cunningham, J.; Lewis,
M. J.; Hu, P. High-Throughput, Automated Protein A Purification
Platform with Multiattribute LC-MS Analysis for Advanced Cell
Culture Process Monitoring. Anal. Chem. 2016, 88, 8673−8679.
(7) Jiang, M.; Severson, K. A.; Love, J. C.; Madden, H.; Swann, P.;
Zang, L.; Braatz, R. D. Opportunities and Challenges of Real-Time
Release Testing in Biopharmaceutical Manufacturing. Biotechnol.
Bioeng. 2017, 114, 2445−2456.
(8) Barnard, G. C.; Kull, A. R.; Sharkey, N. S.; Shaikh, S. S.;
Rittenhour, A. M.; Burnina, I.; Jiang, Y.; Li, F.; Lynaugh, H.; Mitchell,
T.; et al. High-Throughput Screening and Selection of Yeast Cell
Lines Expressing Monoclonal Antibodies. J. Ind. Microbiol. Biotechnol.
2010, 37, 961−971.
(9) Yu, Y.; Mitchell, S.; Lynaugh, H.; Brown, M.; Paul Nobrega, R.;
Zhi, X.; Sun, T.; Caffry, I.; Cao, Y.; Yang, R.; et al. Understanding
Fortebio’s Sensors for High-Throughput Kinetic and Epitope
Screening for Purified Antibodies and Yeast Culture Supernatant. J.
Biomol. Screening 2016, 21, 88−95.
(10) Pedersen, M. E.; Gad, S. I.; Østergaard, J.; Jensen, H. Protein
Characterization in 3D: Size, Folding, and Functional Assessment in a
Unified Approach. Anal. Chem. 2019, 91, 4975−4979.
(11) Jensen, H.; Østergaard, J. Flow Induced Dispersion Analysis
Quantifies Noncovalent Interactions in Nanoliter Samples. J. Am.
Chem. Soc. 2010, 132, 4070−4071.
(12) Poulsen, N. N.; Pedersen, M. E.; Østergaard, J.; Petersen, N. J.;
Nielsen, C. T.; Heegaard, N. H. H.; Jensen, H. Flow-Induced
Dispersion Analysis for Probing Anti-DsDNA Antibody Binding
Heterogeneity in Systemic Lupus Erythematosus Patients: Toward a
New Approach for Diagnosis and Patient Stratification. Anal. Chem.
2016, 88, 9056−9061.
(13) Poulsen, N. N.; Andersen, N. Z.; Østergaard, J.; Zhuang, G.;
Petersen, N. J.; Jensen, H. Flow Induced Dispersion Analysis Rapidly
Quantifies Proteins in Human Plasma Samples. Analyst 2015, 140,
4365−4369.
(14) Pedersen, M. E.; Østergaard, J.; Jensen, H. Flow-Induced
Dispersion Analysis (FIDA) for Protein Quantification and Character-
ization. In Methods in Molecular Biology; Humana Press, 2019.
DOI: 10.1007/978-1-4939-9213-3_8.
(15) To, A. G.; Probes, F.; Technologies, L. Thiol-Reactive Probes
Thiol-Reactive Probes. In The Molecular Probes Handbook: A Guide to
Fluorescent Probes and Labeling Technologies; 2010; pp 96−121.
(16) Nupur, N.; Chhabra, N.; Dash, R.; Rathore, A. S. Assessment of
Structural and Functional Similarity of Biosimilar Products: Rituximab
as a Case Study. mAbs 2018, 10, 143−158.
(17) Justino, C. I. L.; Duarte, A. C.; Rocha-Santos, T. A. P.
Analytical Applications of Affibodies. TrAC Trends Anal. Chem. 2015,
65, 73−82.
(18) Kruljec, N.; Bratkovic,̌ T. Alternative Affinity Ligands for
Immunoglobulins. Bioconjugate Chem. 2017, 28, 2009−2030.
(19) Erickson, H. P. Size and Shape of Protein Molecules at the
Nanometer Level Determined by Sedimentation, Gel Filtration, and
Electron Microscopy. Biol. Proced. Online 2009, 11, 32−51.
(20) Chamieh, J.; Merdassi, H.; Rossi, J. C.; Jannin, V.; Demarne, F.;
Cottet, H. Size Characterization of Lipid-Based Self-Emulsifying
Pharmaceutical Excipients during Lipolysis Using Taylor Dispersion
Analysis with Fluorescence Detection. Int. J. Pharm. 2018, 537, 94−
101.
(21) Satzer, P.; Jungbauer, A. High-Capacity Protein A Affinity
Chromatography for the Fast Quantification of Antibodies: Two-
Wavelength Detection Expands Linear Range. J. Sep. Sci. 2018, 41,
1791−1797.
(22) Willoughby, N.; Martin, P.; Titchener-Hooker, N. Extreme
Scale-down of Expanded Bed Adsorption: Purification of an Antibody
Fragment Directly from Recombinant E Coli Culture. Biotechnol.
Bioeng. 2004, 87, 641−647.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00791
ACS Omega 2020, 5, 10519−10524
10524
